Form 4: Syros Pharmaceuticals Director Acquires Shares and Stock Options

Director Marsha Fanucci acquired 4,000 shares of common stock and stock options for 6,000 shares of Syros Pharmaceuticals on June 5, 2024.

Summary

• On June 5, 2024, Marsha Fanucci, a director of Syros Pharmaceuticals, acquired 4,000 shares of common stock at $0.00 per share.
• Following this transaction, Fanucci directly owns 16,000 shares of common stock.
• Fanucci also acquired stock options for 6,000 shares of common stock with an exercise price of $5.30.
• The options vest over a one-year period, with 50% vesting after six months and the remainder vesting monthly.
• Following the transaction, Fanucci directly owns options for 6,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and options by a director could be interpreted as a slightly positive signal, but it's not a major event.

Positives

• A director's acquisition of shares and options can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Stock Options, Common Stock, Beneficial Ownership, Form 4, Acquisition